2 min read
Vietnam is quickly becoming one of Southeast Asia’s most attractive pharmaceutical markets, and regulators are making sure the approval system evolves with that growth.
In April 2026, Vietnam’s Ministry of Health announced amendments to its drug registration framework to make approvals faster, improve transparency, and encourage digital transformation in pharmaceutical submissions. These changes could significantly impact how global pharmaceutical companies register products in Vietnam.
For companies planning market expansion in Southeast Asia, this is a major opportunity, but only if they adapt quickly.
Why Vietnam Is Updating Drug Registration Rules
Vietnam has faced growing pressure to speed up access to medicines while reducing registration bottlenecks.
To address this, the Ministry of Health is revising provisions under Circular No. 12/2025/TT-BYT, which currently governs marketing authorization registration for drugs and pharmaceutical raw materials.
The latest amendments aim to:
- Simplify registration requirements
- Improve transparency
- Increase digitalization in dossier review
- Reduce approval delays
- Align Vietnam with global Regulatory standards
This signals Vietnam’s broader push to modernize its pharmaceutical Regulatory ecosystem.
Key Changes Pharma Companies Should Watch
Easier Certificate of Pharmaceutical Product (CPP) Requirements
Previously, companies often faced documentation hurdles during submission.
Under recent reforms:
- Only one CPP may be required
- CPPs from recognized Regulatory authorities may be accepted
- Documentation requirements are becoming less burdensome
This could help reduce delays for international manufacturers.
Increased Use of Reference Authority Approvals
Vietnam is increasingly recognizing approvals from major Regulatory agencies, such as:
- European Medicines Agency (European Medicines Agency)
- U.S. Food and Drug Administration
- Pharmaceuticals and Medical Devices Agency (Japan)
This may allow faster approvals for products already approved in major global markets.
Greater Focus on Digital Submissions
Vietnam regulators are actively promoting digital transformation by:
- Moving toward electronic submissions
- Improving online dossier tracking
- Streamlining Regulatory reviews
For companies still relying on manual processes, this shift may require operational adjustments.
Faster Review Timelines
Recent reforms are designed to reduce approval timelines for both domestic and imported drugs.
Imported drug approvals may move significantly faster when dossiers are complete and aligned with requirements.
That creates faster market opportunities but leaves less room for submission errors.
Stronger Compliance Expectations
While approvals may become faster, regulators are also tightening scrutiny around:
- Manufacturing documentation
- Stability data
- Quality compliance
- Product traceability
The Drug Administration of Vietnam is clearly balancing speed with stronger oversight.
What This Means for Global Pharma Companies
These reforms create significant opportunities for:
- Pharmaceutical manufacturers
- Biotech companies
- Generic drug companies
- API manufacturers
- Companies expanding into ASEAN markets
But success will depend on:
- Strong dossier preparation
- Faster submission readiness
- Local Regulatory expertise
- Ongoing compliance support
Companies that fail to adapt may face approval delays despite Vietnam’s efforts to streamline processes.
Why Local Regulatory Support Matters
Vietnam’s evolving Regulatory environment can be challenging for foreign manufacturers unfamiliar with local requirements.
A strong local Regulatory partner can help companies:
- Prepare compliant dossiers
- Manage submissions
- Handle authority communication
- Reduce approval delays
- Maintain post-approval compliance
As Vietnam accelerates Regulatory reforms, local expertise will become a competitive advantage.
How Freyr Can Help
Freyr supports pharmaceutical companies with:
- Vietnam drug registration
- Regulatory strategy
- Market entry planning
- Lifecycle maintenance
- Post-approval compliance
If Vietnam is part of your ASEAN growth strategy, now is the time to prepare.
